Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
The STEADY diabetic foot ulcer registry: methods, insights, and future directions.
Journal: Wounds : a compendium of clinical research and practice
Published: June 19, 2026
TWO2 Therapy Demonstrates Clinically Meaningful Long-Term Outcomes Compared to Other Advanced Wound Care Modalities: Real-World Evidence Supported by Mechanistic and RCT Clinical Data.
Journal: Journal of clinical medicine
Published: May 13, 2026
Toward a practical framework for debridement in chronic wounds: findings from a United States-based multidisciplinary consensus panel.
Journal: Wounds : a compendium of clinical research and practice
Published: April 16, 2026
Walking the Line: How Social Forces Shape Diabetic Foot Outcomes in the Texas Rio Grande Valley.
Journal: Clinics in podiatric medicine and surgery
Published: March 19, 2026
Understanding DREADD (Diabetes-Related Extremity Amputation Depression and Distress).
Journal: Clinics in podiatric medicine and surgery
Published: March 19, 2026
Bromelain-based debridement versus collagenase ointment debridement of venous leg ulcers: post hoc analysis of the ChronEx trial.
Journal: Wounds : a compendium of clinical research and practice
Published: May 14, 2025
Diabetes-Related Extremity Amputation Depression and Distress (DREADD): A Multimethod Study.
Journal: Seminars in vascular surgery
Published: September 07, 2024
Once daily Bromelain-based enzymatic debridement of venous leg ulcers versus gel vehicle (placebo) and non-surgical standard of care: a three-arm multicenter, double blinded, randomized controlled study.
Journal: EClinicalMedicine
Published: January 27, 2024
An open-label, proof-of-concept study assessing the effects of bromelain-based enzymatic debridement on biofilm and microbial loads in patients with venous leg ulcers and diabetic foot ulcers.
Journal: Wounds : a compendium of clinical research and practice
Published: January 26, 2024
Gene therapy for diabetic foot ulcers: Interim analysis of a randomised, placebo-controlled phase 3 study of VM202 (ENGENSIS), a plasmid DNA expressing two isoforms of human hepatocyte growth factor.
Journal: International wound journal
Published: February 24, 2023
Last Updated: 09/26/2026